RTFCCR/LUNGevity Award for Overcoming Treatment Resistance

A co-funded partnership between LUNGevity Foundation and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR), this award provides up to $1,000,000 per project over four years ($500,000 from each partner) for early-phase interventional clinical trial research on lung cancer treatment resistance. Three focus areas: overcoming resistance to lung cancer therapies, lab-developed tests for monitoring treatment response or resistance, and technologies for earlier recurrence detection.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.